DK0795324T3 - En farmaceutisk tablet kendetegnet ved, at den udviser stor volumenforögelse, når den kommer i kontakt med biologiske væsker - Google Patents

En farmaceutisk tablet kendetegnet ved, at den udviser stor volumenforögelse, når den kommer i kontakt med biologiske væsker

Info

Publication number
DK0795324T3
DK0795324T3 DK97102567T DK97102567T DK0795324T3 DK 0795324 T3 DK0795324 T3 DK 0795324T3 DK 97102567 T DK97102567 T DK 97102567T DK 97102567 T DK97102567 T DK 97102567T DK 0795324 T3 DK0795324 T3 DK 0795324T3
Authority
DK
Denmark
Prior art keywords
contact
exhibits
comes
large volume
biological fluids
Prior art date
Application number
DK97102567T
Other languages
Danish (da)
English (en)
Inventor
Ubaldo Conte
Lauretta Maggi
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec Ag filed Critical Jagotec Ag
Application granted granted Critical
Publication of DK0795324T3 publication Critical patent/DK0795324T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
DK97102567T 1996-02-19 1997-02-18 En farmaceutisk tablet kendetegnet ved, at den udviser stor volumenforögelse, når den kommer i kontakt med biologiske væsker DK0795324T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96MI000311A IT1282650B1 (it) 1996-02-19 1996-02-19 Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici

Publications (1)

Publication Number Publication Date
DK0795324T3 true DK0795324T3 (da) 2004-08-16

Family

ID=11373320

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97102567T DK0795324T3 (da) 1996-02-19 1997-02-18 En farmaceutisk tablet kendetegnet ved, at den udviser stor volumenforögelse, når den kommer i kontakt med biologiske væsker

Country Status (12)

Country Link
US (1) US5780057A (fr)
EP (2) EP1382331B1 (fr)
JP (1) JP3251190B2 (fr)
AT (2) ATE530173T1 (fr)
AU (1) AU719170B2 (fr)
CA (1) CA2197941C (fr)
DE (1) DE69728710T2 (fr)
DK (1) DK0795324T3 (fr)
ES (2) ES2219709T3 (fr)
IT (1) IT1282650B1 (fr)
NZ (1) NZ314265A (fr)
PT (1) PT795324E (fr)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US5804165A (en) * 1996-07-24 1998-09-08 Arnold; Michael J. Antiplaque oral composition
DE19640062B4 (de) * 1996-09-28 2006-04-27 Lts Lohmann Therapie-Systeme Ag Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
IT1294760B1 (it) * 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
IN186245B (fr) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
PE20000066A1 (es) * 1997-12-22 2000-02-09 Schering Corp Formas de dosificacion solida de ribavirina administrables oralmente y proceso de fabricacion
WO1999062560A1 (fr) * 1998-06-05 1999-12-09 Warner-Lambert Company Stabilisation de compositions contenant des inhibiteurs de l'enzyme de conversion d'angiotensine utilisant de l'oxyde de magnesium
AU761281B2 (en) * 1998-09-25 2003-05-29 Delsys Pharmaceutical Corporation Liquid pharmaceutical for oral delivery
JP2002531491A (ja) 1998-12-11 2002-09-24 ノストラム・ファーマスーティカルズ・インコーポレイテッド ヒドロコロイドおよびセルロースエーテルを含む持続放出性錠剤
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
MY121470A (en) * 1999-05-03 2006-01-28 Ranbaxy Lab Ltd Stable solid pharmaceutical compositions containing enalapril maleate
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
FR2797185B1 (fr) * 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
JP4565456B2 (ja) * 1999-11-02 2010-10-20 塩野義製薬株式会社 着色顆粒の色素定着法
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
JP2004501190A (ja) * 2000-06-23 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6881420B2 (en) 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
BR0115585A (pt) 2000-11-28 2005-12-13 Fmc Corp Composições de revestimento de pronta liberação, endurecìvel, comestìvel, seca e, úmida, forma de dosagem sólida, e, método para revestir uma forma de dosagem sólida farmacêutica ou veterinária, confeito, semente, ração animal, fertilizante, comprimido de pesticida ou alimento
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
WO2002045695A2 (fr) * 2000-12-05 2002-06-13 Alexander Macgregor Systeme de distribution hydrostatique regulee d'un agent
KR100685945B1 (ko) 2000-12-29 2007-02-23 엘지.필립스 엘시디 주식회사 액정표시장치 및 그 제조방법
US8268333B2 (en) * 2001-04-24 2012-09-18 Lintec Corporation Orally administered agent and an orally administered agent/supporting substrate complex
DE10120092B4 (de) * 2001-04-25 2008-03-20 Lts Lohmann Therapie-Systeme Ag Magensaftresistente Vorrichtung zur Freisetzung von mukoadhäsiven Wirkstoffträgern und Verfahren zur Herstellung der magensaftresistenten Vorrichtung
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
IL159812A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CA2409552A1 (fr) 2001-10-25 2003-04-25 Depomed, Inc. Forme posologique orale pouvant etre retenue dans l'estomac dont la liberation est limitee a la partie inferieure du tube digestif
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
AU2002346372A1 (en) * 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. Process for the production of l-dopa ethyl ester
WO2003041646A2 (fr) 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. Sels de l-dopa ethylester et leurs utilisations
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
CA2470342C (fr) * 2001-12-21 2010-05-11 Biopartners Gmbh Granulat de ribavirine pour la production de comprimes pellicules
KR20030056474A (ko) * 2001-12-28 2003-07-04 한국유나이티드제약 주식회사 카르비도파/레보도파 서방정의 조성물과 그의 제조방법
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
CN1630513A (zh) * 2002-02-04 2005-06-22 兰贝克赛实验室有限公司 流体动力平衡的以两相释放的口服药物输递系统
US7008979B2 (en) * 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
AR041744A1 (es) * 2002-10-31 2005-05-26 Alza Corp Formas de dosificacion que proporcionan la liberacion ascendente de una formulacion liquida
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
EP1701725B1 (fr) * 2003-12-16 2013-07-31 Relevare Aust. Pty Ltd Compositions comprenant le flupiritne et un opioide pour le traitement de la douleur neuropathique
WO2005079752A2 (fr) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Compositions pharmaceutiques a liberation controlee presentant une meilleure biodisponibilite
JPWO2005084703A1 (ja) * 2004-03-09 2007-11-29 株式会社Ｎｒｌファーマ 徐放性の口腔用組成物
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
ES2531735T3 (es) * 2004-10-15 2015-03-18 Supernus Pharmaceuticals, Inc. Preparaciones farmacéuticas con menor potencial de abuso
US8858960B2 (en) * 2004-11-19 2014-10-14 GlaxoSmithKline, LLC Method of producing a pharmaceutical product
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
MX2007007836A (es) * 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Metodo para estabilizar un farmaco anti-demencia.
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
CA2613631A1 (fr) * 2005-06-23 2007-01-04 Spherics, Inc. Formes de dosage ameliorees pour le traitement de troubles moteurs
US20090099154A1 (en) * 2005-06-29 2009-04-16 Panacea Biotec Ltd. Pharmaceutical Sustained Release Compositions and Processes Thereof
PT1931346E (pt) * 2005-09-09 2012-08-14 Angelini Labopharm Llc Composição de trazodona para administração uma vez por dia
WO2007048219A2 (fr) * 2005-09-09 2007-05-03 Labopharm Inc. Composition medicamenteuse a liberation prolongee
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
US8187633B2 (en) 2005-11-03 2012-05-29 Sun Pharma Advanced Research Company Limited Controlled release coated tablets having prolonged gastric retention
WO2007056570A2 (fr) * 2005-11-07 2007-05-18 Teva Pharmaceutical Industries Ltd. Compositions de levodopa
US7674396B2 (en) * 2005-11-08 2010-03-09 Plensat Llc Method and system for treatment of eating disorders
US8691272B2 (en) 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
KR100752417B1 (ko) * 2006-02-14 2007-08-28 대원제약주식회사 안정성이 증진된, 마진돌을 포함하는 약제학적 조성물
US9011930B2 (en) * 2006-05-01 2015-04-21 Zycal Bioceuticals Healthcare Company, Inc. Nutritional supplement and use thereof
US20090285862A1 (en) * 2006-05-03 2009-11-19 Cnsbio Pty Ltd. Methods and composition for treatment of inflammatory pain
CA2654402A1 (fr) * 2006-06-01 2007-12-06 Adel Penhasi Formulation pharmaceutique comprenant des unites multiples
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
CA2662123C (fr) 2006-08-30 2015-12-01 Jagotec Ag Formulations posologiques a liberation controlee administrees par voie orale comprenant un noyau et une ou plusieurs couches barrieres
WO2008039193A2 (fr) * 2006-09-26 2008-04-03 Plensat, Llc Méthode et système de traitement de troubles de l'alimentation
BRPI0622039B1 (pt) * 2006-09-26 2020-11-10 Plensat, Llc dispositivos gástricos ingeríveis de qualidade alimentícia
EP2067475A4 (fr) 2006-09-26 2010-12-15 Astellas Pharma Inc Préparation à libération entretenue de tacrolimus
EP1935411A1 (fr) 2006-12-15 2008-06-25 Campina Nederland Holding B.V. Excipient à libération prolongée et son utilisation
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
US20090011018A1 (en) * 2006-12-28 2009-01-08 Astellas Pharma Inc., Sustained release formulation for tacrolimus
AT505225A1 (de) 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
AU2009268934A1 (en) * 2008-06-16 2010-01-14 Appian Labs, Llc Composition and method of preparation of release systems for constant (zero-order) release of active agents
CN102202656A (zh) * 2008-08-15 2011-09-28 蒂宝制药公司 治疗和预防cns障碍的胃滞留药用组合物
WO2010041279A2 (fr) * 2008-10-08 2010-04-15 V.B. Medicare Pvt. Ltd. Système d'administration de médicaments à libération prolongée
US20100112054A1 (en) * 2008-10-23 2010-05-06 Appian Labs, Llc Tablets and discs with compartments with two or more drugs for release at certain intervals and with specific rates
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
EP2210585A1 (fr) 2009-01-16 2010-07-28 Exelgyn Compositions pharmaceutiques SPRM et procédés de traitement les utilisant
US20100249423A1 (en) * 2009-03-09 2010-09-30 Sanochemia Pharmazeutika Ag Tolperisone controlled release tablet
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US10485770B2 (en) 2009-12-21 2019-11-26 Aptapharma, Inc. Functionally-coated multilayer tablets
ES2665467T3 (es) 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
JP5459670B2 (ja) * 2010-05-07 2014-04-02 塩野義製薬株式会社 着色顆粒の色素定着化剤
US20130143867A1 (en) * 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2013213317B2 (en) 2012-01-23 2016-06-30 Sun Pharmaceutical Industries Limited In-situ multilayered tablet technology
WO2014197744A1 (fr) 2013-06-05 2014-12-11 Synchroneuron, Inc. Formulations d'acamprosate, procédés d'utilisation de celles-ci, et combinaisons comprenant celles-ci
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
WO2015187746A1 (fr) 2014-06-02 2015-12-10 Teva Pharmaceutical Industries Ltd. Forme posologique à rétention gastrique expansible
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
EP3247384B1 (fr) 2015-01-14 2023-10-04 The Regents of the University of Colorado, a body corporate Méthode de diagnostique in vitro du diabète de type 1 avec des mimotopes de l'insuline
US20180036382A1 (en) * 2015-02-09 2018-02-08 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
WO2017165508A1 (fr) 2016-03-24 2017-09-28 Im Therapeutics Méthodes de traitement d'une maladie auto-immune
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN116850132A (zh) 2016-08-17 2023-10-10 安提拉生物有限公司 用于口服的活性剂的制剂
CN110035718B (zh) 2016-12-02 2021-04-06 克雷西奥生物科技有限公司 胃内滞留系统
KR102039345B1 (ko) * 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 고팽윤성 서방성 삼중정제
US11332438B2 (en) 2017-12-01 2022-05-17 Ultragenyx Pharmaceutical Inc. Creatine prodrugs, compositions and methods of use thereof
WO2019111132A1 (fr) 2017-12-04 2019-06-13 Clexio Biosciences Ltd. Système de résidence gastrique à action prolongée
CA3097737A1 (fr) 2017-12-18 2019-06-27 Tris Pharma, Inc. Compositions pharmaceutiques comprenant un systeme formant un reseau polymere d'interpenetration flottant
WO2019126214A1 (fr) 2017-12-18 2019-06-27 Tris Pharma, Inc. Composition pharmaceutique comprenant des systèmes formant un radeau de rétention gastrique de ghb à libération de médicament par impulsions de déclenchement
CA3085941A1 (fr) 2017-12-18 2019-06-27 Tris Pharma, Inc. Compositions pharmaceutiques de ghb comprenant un systeme de formation de reseau polymere interpenetrant flottant
AU2018388577B2 (en) 2017-12-18 2024-06-06 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
KR102942294B1 (ko) * 2018-05-15 2026-03-23 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 소분자 이지에프알 억제제를 포함하는 약학 조성물 및 그의 제조 방법
CN110214860A (zh) * 2019-07-10 2019-09-10 聂刘明 一种宠物饲料及其制备工艺
KR20230124622A (ko) 2020-12-22 2023-08-25 암닐 파마슈티컬스 엘엘씨 레보도파 투여 요법
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12409163B2 (en) 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
BR112024001927A2 (pt) * 2021-07-30 2024-04-30 Evecxia Therapeutics Inc Formas de dosagem gastrorretentivas de 5-hidroxitriptofano
EP4392031A4 (fr) 2021-10-14 2025-07-30 Evecxia Therapeutics Inc Méthode d'optimisation de la fonction de la 5-hydroxytryptamine dans le cerveau à des fins thérapeutiques
WO2023214018A1 (fr) 2022-05-06 2023-11-09 Galenix Innovations Composition à libération prolongée gonflable à rétention gastrique
JP2026513019A (ja) 2023-02-03 2026-04-22 トリス・フアルマ・インコーポレーテツド １晩１回の低ナトリウムオキシベート組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4839171A (en) * 1984-11-30 1989-06-13 Techmix, Inc. Composition for treating impaired lactation
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
JPH0747534B2 (ja) * 1986-06-02 1995-05-24 ロ−ラ−ジヤパン株式会社 錠 剤
US4869908A (en) * 1987-01-09 1989-09-26 K.V. Pharmaceutical Co. Fibre formulations
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time

Also Published As

Publication number Publication date
AU1477697A (en) 1997-08-28
IT1282650B1 (it) 1998-03-31
CA2197941A1 (fr) 1997-08-20
EP0795324B1 (fr) 2004-04-21
ES2376199T8 (es) 2012-04-04
PT795324E (pt) 2004-09-30
ATE530173T1 (de) 2011-11-15
ES2219709T3 (es) 2004-12-01
ITMI960311A0 (fr) 1996-02-19
DE69728710D1 (de) 2004-05-27
DE69728710T2 (de) 2005-04-07
JPH09316005A (ja) 1997-12-09
EP1382331A1 (fr) 2004-01-21
EP1382331B1 (fr) 2011-10-26
NZ314265A (en) 1997-07-27
ITMI960311A1 (it) 1997-08-19
EP0795324A2 (fr) 1997-09-17
ES2376199T3 (es) 2012-03-09
EP0795324A3 (fr) 1998-11-04
AU719170B2 (en) 2000-05-04
ATE264670T1 (de) 2004-05-15
CA2197941C (fr) 2001-12-04
JP3251190B2 (ja) 2002-01-28
US5780057A (en) 1998-07-14

Similar Documents

Publication Publication Date Title
DK0795324T3 (da) En farmaceutisk tablet kendetegnet ved, at den udviser stor volumenforögelse, når den kommer i kontakt med biologiske væsker
ATE173159T1 (de) Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
FI924247A0 (fi) En doseringsform foer frigoerande av medicin till tarmen.
FI940787A0 (fi) Annostusmuoto lääkkeen annostelemiseksi lyhyessä ajanjaksossa
CA2264250A1 (fr) Comprime a liberation controlee de chlorhydrate d'alfuzosine
DE69522729D1 (de) Arzneimittel zum Wirkstoff - Targetting in den Dickdarm
KR880013586A (ko) 고체상태성질을 가진 제거 가능한 기질을 포함하는 투약기
ATE71293T1 (de) Arzneiformulierung.
RU99118887A (ru) Применение ингибиторов желудочно-кишечной липазы
DK0724885T3 (da) Pernasal sammensætning og pernasalt præparat indeholdende dette
ATE122880T1 (de) Mehrfach teilbare tablettenstruktur.
CA2383212A1 (fr) Dosage oral a liberation regulee destine a l'administration orale
Cathcart III The method of determining proper doses of vitamin C for the treatment of disease by titrating to bowel tolerance
ATE304844T1 (de) Entzündungshemmende pharmazeutische formulierungen
KR950013513A (ko) 약제 제조용 모에노마이신 및 이의 유도체, 및 모에노마이신 또는 이의 유도체를 함유하는 약제
BR0109917A (pt) Método de administração oral e composição para medicamentos sólidos ou suplementos dietéticos
KR870009716A (ko) 클로르페니라민 제형
RU2002121267A (ru) Способ профилактики и лечения язв желудка у животных
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
SE9700617D0 (sv) New composition
Pawar et al. A review on gastro retentive drug delivery system (GRDDS)
Vlak et al. Comparative approach to gastrointestinal side effects of tenoxicam and other antirheumatics administered to patients with rheumatoid arthritis.
WO2002028430A3 (fr) Traitement de l'arthrite rhumatoide juvenile par administration orale d'un pool d'immunoglobuline humaine et d'un antiacide
Fonken Tips for taking Norvir (Ritonavir) oral solution
IT1265224B1 (it) Composizioni farmaceutiche per uso orale per il trattamento delle manifestazioni ulcerose gastro-duodenali ed esofagee